BLAINJECTIONINJECTABLEPriority Review
Approved
Mar 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
6/8 — Strong
Priority Review
YERVOY (ipilimumab) by Bristol Myers Squibb is ctla-4-directed antibody interactions [moa]. Approved for melanoma, non-small cell lung cancer, hepatocellular carcinoma and 2 more indications. First approved in 2011.
YERVOY (ipilimumab) is a monoclonal antibody that blocks CTLA-4, a checkpoint protein that suppresses immune responses, thereby enabling the body's immune system to attack cancer cells. Approved by the FDA on March 25, 2011, it represents a foundational immunotherapy mechanism. YERVOY is used in melanoma and other malignancies where checkpoint inhibition can enhance anti-tumor immunity. It established the clinical proof-of-concept for the entire checkpoint inhibitor class and remains a standard-of-care component in combination regimens, though increasingly used alongside PD-1/PD-L1 inhibitors.
$0.0BPart D
Mechanism of Action
CTLA-4-directed Antibody Interactions
Pharmacologic Class:
CTLA-4-directed Blocking Antibody
Indications (5)
Worked on YERVOY at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.